Trial Profile
Phase II study of weekly 1-hour paclitaxel (Taxol) plus recombinant humanized anti-p 185HER2 monoclonal antibody (Herceptin) [trastuzumab] in the treatment of patients with metastatic breast cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 08 Sep 2005 New trial record.